Alzheimer's Research & Therapy最新文献

{"title":"Impact of cumulative exposure to anticholinergic and sedative drugs on cognition in older adults: a memory clinic cohort study.","authors":"Elsa Reallon, Frédéric Gervais, Claire Moutet, Virginie Dauphinot, Pauline Desnavailles, Teddy Novais, Pierre Krolak-Salmon, Antoine Garnier-Crussard, Christelle Mouchoux","doi":"10.1186/s13195-024-01530-8","DOIUrl":"10.1186/s13195-024-01530-8","url":null,"abstract":"<p><strong>Background: </strong>Long-term exposure to anticholinergic and sedative drugs could be a modifiable risk factor for cognitive decline. The objective of this study was to measure the association between previous cumulative anticholinergic and sedative drug exposure (Drug Burden Index) and cognitive decline.</p><p><strong>Methods: </strong>A cohort study (MEMORA cohort) was conducted in a French memory clinic for patients attending a consultation between November 2014 and December 2020, with at least 2 Mini-Mental State Examination (MMSE) measurements (≥ 6 months apart) and available medication data from the local Primary Health Insurance Fund database (n = 1,970). Drug Burden Index was linearly cumulated until each MMSE measurement and was used to categorise patients according to their level of exposure (no exposure, moderate, or high). The longitudinal association between Drug Burden Index and MMSE was assessed using a multivariate linear mixed model, adjusted for age, education level, anxiety disorders, depressive disorders, functional autonomy, and behavioural disorders.</p><p><strong>Results: </strong>Overall, 1,970 patients were included with a mean follow-up duration of 2.78 years (± 1.54) and 2.99 visits per patients (5,900 MMSE + Drug Burden Index measurements collected). At baseline, 68.0% of patients had moderate cumulative anticholinergic and sedative drug exposure and a mean MMSE of 21.1. MMSE decrease was steeper in patients with moderate and high Drug Burden Index ( -1.74 and -1.70/year, respectively) than in patients with no exposure (-1.26/year) after adjusting for age, education, anxiety and depressive disorders, functional autonomy, and behavioural disorders (p < 0.01).</p><p><strong>Conclusions: </strong>Long-term exposure to anticholinergic and sedative drugs is associated with steeper cognitive decline. Medication review focusing on de-prescribing these drugs could be implemented early to reduce cognitive impairment.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"163"},"PeriodicalIF":7.9,"publicationDate":"2024-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141750878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormone therapy is associated with lower Alzheimer's disease tau biomarkers in post-menopausal females -evidence from two independent cohorts.","authors":"Yi-Ting Wang, Joseph Therriault, Cécile Tissot, Stijn Servaes, Nesrine Rahmouni, Arthur Cassa Macedo, Jaime Fernandez-Arias, Sulantha S Mathotaarachchi, Jenna Stevenson, Firoza Z Lussier, Andréa L Benedet, Tharick A Pascoal, Nicholas J Ashton, Henrik Zetterberg, Kaj Blennow, Serge Gauthier, Pedro Rosa-Neto","doi":"10.1186/s13195-024-01509-5","DOIUrl":"10.1186/s13195-024-01509-5","url":null,"abstract":"<p><strong>Background: </strong>Females represent approximately 70% of the Alzheimer's disease (AD) cases and the literature has proposed a connection between the decreased estrogen levels during menopause and an increased AD risk. Previous investigations have predominantly focused on assessing how hormone therapy (HT) affects the likelihood of AD development and cognitive deterioration. However, as the research framework has shifted toward a biomarker-defined AD and alterations in specific biomarkers could take place years before cognitive decline becomes discernible, it is crucial to examine how HT influences AD biomarkers. The main goal of this study was to evaluate the impact of HT on AD biomarker-informed pathophysiology in both cognitively unimpaired (CU) and cognitively impaired (CI) post-menopausal females across the aging and AD spectrum.</p><p><strong>Methods: </strong>This cross-sectional study included post-menopausal females without HT history (HT-) and with HT (HT+) at the time of PET imaging assessment from two cohorts: the Translational Biomarkers in Aging and Dementia (TRIAD) cohort, and the Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants underwent magnetic resonance imaging (MRI), positron emission tomography (PET) and biofluid collection. Voxel-based t-tests were performed to assess the differences in amyloid-β (Aβ) and tau neurofibrillary tangles (NFTs) loads between HT- and HT + females. Linear regression models with interaction terms were also conducted to examine the interactive effects of HT and Aβ-PET on regional tau-PET.</p><p><strong>Results: </strong>HT + females demonstrated significantly lower tau-PET standardized uptake value ratio (SUVR) in Braak I-II ROIs (P < 0.05, Hedges' g = 0.73), Braak III-IV ROIs (P < 0.0001, Hedges' g = 0.74) and Braak V-VI ROIs (P < 0.0001, Hedges' g = 0.69) compared to HT- females. HT + females also showed significantly lower CSF p-tau₁₈₁ (P < 0.001) and plasma p-tau₁₈₁ (P < 0.0001) concentrations. Additionally, results from multivariate linear regression models indicated that HT interacts with cortical Aβ and is associated with lower regional NFT load.</p><p><strong>Conclusions: </strong>Overall, findings from this observational study suggest that HT is associated with lower tau neuroimaging and fluid biomarkers in postmenopausal females. Due to the close link between tau and cognition, this study highlights the need for large randomized controlled trials designed to systemically study the influences of HT on AD biomarkers and disease progression.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"162"},"PeriodicalIF":7.9,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141733255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alpha-lipoic acid alleviates cognitive deficits in transgenic APP23/PS45 mice through a mitophagy-mediated increase in ADAM10 α-secretase cleavage of APP.","authors":"Jie Zhang, Yanshuang Jiang, Xiangjun Dong, Zijun Meng, Liangye Ji, Yu Kang, Mingjing Liu, Weihui Zhou, Weihong Song","doi":"10.1186/s13195-024-01527-3","DOIUrl":"10.1186/s13195-024-01527-3","url":null,"abstract":"<p><strong>Background: </strong>Alpha-lipoic acid (ALA) has a neuroprotective effect on neurodegenerative diseases. In the clinic, ALA can improve cognitive impairments in patients with Alzheimer's disease (AD) and other dementias. Animal studies have confirmed the anti-amyloidosis effect of ALA, but its underlying mechanism remains unclear. In particular, the role of ALA in amyloid-β precursor protein (APP) metabolism has not been fully elucidated.</p><p><strong>Objective: </strong>To investigate whether ALA can reduce the amyloidogenic effect of APP in a transgenic mouse model of AD, and to study the mechanism underlying this effect.</p><p><strong>Methods: </strong>ALA was infused into 2-month-old APP23/PS45 transgenic mice for 4 consecutive months and their cognitive function and AD-like pathology were then evaluated. An ALA drug concentration gradient was applied to 20E2 cells in vitro to evaluate its effect on the expression of APP proteolytic enzymes and metabolites. The mechanism by which ALA affects APP processing was studied using GI254023X, an inhibitor of A Disintegrin and Metalloproteinase 10 (ADAM10), as well as the mitochondrial toxic drug carbonyl cyanide m-chlorophenylhydrazone (CCCP).</p><p><strong>Results: </strong>Administration of ALA ameliorated amyloid plaque neuropathology in the brain tissue of APP23/PS45 mice and reduced learning and memory impairment. ALA also increased the expression of ADAM10 in 20E2 cells and the non-amyloidogenic processing of APP to produce the 83 amino acid C-terminal fragment (C83). In addition to activating autophagy, ALA also significantly promoted mitophagy. BNIP3L-knockdown reduced the mat/pro ratio of ADAM10. By using CCCP, ALA was found to regulate BNIP3L-mediated mitophagy, thereby promoting the α-cleavage of APP.</p><p><strong>Conclusions: </strong>The enhanced α-secretase cleavage of APP by ADAM10 is the primary mechanism through which ALA ameliorates the cognitive deficits in APP23/PS45 transgenic mice. BNIP3L-mediated mitophagy contributes to the anti-amyloid properties of ALA by facilitating the maturation of ADAM10. This study provides novel experimental evidence for the treatment of AD with ALA.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"160"},"PeriodicalIF":7.9,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264788/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141726738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High cognitive reserve attenuates the risk of dementia associated with cardiometabolic diseases.","authors":"Abigail Dove, Wenzhe Yang, Serhiy Dekhtyar, Jie Guo, Jiao Wang, Anna Marseglia, Davide Liborio Vetrano, Rachel A Whitmer, Weili Xu","doi":"10.1186/s13195-024-01528-2","DOIUrl":"10.1186/s13195-024-01528-2","url":null,"abstract":"<p><strong>Background: </strong>Cardiometabolic diseases (CMDs) including type 2 diabetes, heart disease, and stroke have been linked to a higher risk of dementia. We examined whether high levels of cognitive reserve (CR) can attenuate the increased dementia risk and brain pathologies associated with CMDs.</p><p><strong>Methods: </strong>Within the UK Biobank, 216,178 dementia-free participants aged ≥ 60 were followed for up to 15 years. Baseline CMDs and incident dementia were ascertained from medical records, medication use, and medical history. Latent class analysis was used to generate an indicator of CR (low, moderate, and high) based on education, occupational attainment, confiding in others, social contact, leisure activities, and television watching time. A subsample (n = 13,663) underwent brain MRI scans during follow-up. Volumes of total gray matter (GMV), hippocampus (HV), and white matter hyperintensities (WMHV) were ascertained, as well as mean diffusivity (MD) and fractional anisotropy (FA) in white matter tracts.</p><p><strong>Results: </strong>At baseline, 43,402 (20.1%) participants had at least one CMD. Over a mean follow-up of 11.7 years, 6,600 (3.1%) developed dementia. The presence of CMDs was associated with 57% increased risk of dementia (HR 1.57 [95% CI 1.48, 1.67]). In joint effect analysis, the HRs of dementia for people with CMDs and moderate-to-high CR and low CR were 1.78 [1.66, 1.91] and 2.13 [1.97, 2.30]), respectively (reference: CMD-free, moderate-to-high CR). Dementia risk was 17% lower (HR 0.83 [0.77, 0.91], p < 0.001) among people with CMDs and moderate-to-high compared to low CR. On brain MRI, CMDs were associated with smaller GMV (β -0.18 [-0.22, -0.13]) and HV (β -0.13 [-0.18, -0.08]) as well as significantly larger WMHV (β 0.06 [0.02, 0.11]) and MD (β 0.08 [0.02, 0.13]). People with CMDs and moderate-to-high compared to low CR had significantly larger GMV and HV, but no differences in WMHV, MD, or FA.</p><p><strong>Conclusions: </strong>Among people with CMDs, having a higher level of CR was associated with lower dementia risk and larger gray matter and hippocampal volumes. The results highlight a mentally and socially active life as a modifiable factor that may support cognitive and brain health among people with CMDs.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"161"},"PeriodicalIF":7.9,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141726739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can white matter hyperintensities based Fazekas visual assessment scales inform about Alzheimer’s disease pathology in the population?","authors":"Aishwarya Pradeep, Sheelakumari Raghavan, Scott A. Przybelski, Gregory M. Preboske, Christopher G. Schwarz, Val J. Lowe, David S. Knopman, Ronald C. Petersen, Clifford R. Jack, Jonathan Graff-Radford, Petrice M. Cogswell, Prashanthi Vemuri","doi":"10.1186/s13195-024-01525-5","DOIUrl":"https://doi.org/10.1186/s13195-024-01525-5","url":null,"abstract":"White matter hyperintensities (WMH) are considered hallmark features of cerebral small vessel disease and have recently been linked to Alzheimer’s disease (AD) pathology. Their distinct spatial distributions, namely periventricular versus deep WMH, may differ by underlying age-related and pathobiological processes contributing to cognitive decline. We aimed to identify the spatial patterns of WMH using the 4-scale Fazekas visual assessment and explore their differential association with age, vascular health, AD imaging markers, namely amyloid and tau burden, and cognition. Because our study consisted of scans from GE and Siemens scanners with different resolutions, we also investigated inter-scanner reproducibility and combinability of WMH measurements on imaging. We identified 1144 participants from the Mayo Clinic Study of Aging consisting of a population-based sample from Olmsted County, Minnesota with available structural magnetic resonance imaging (MRI), amyloid, and tau positron emission tomography (PET). WMH distribution patterns were assessed on FLAIR-MRI, both 2D axial and 3D, using Fazekas ratings of periventricular and deep WMH severity. We compared the association of periventricular and deep WMH scales with vascular risk factors, amyloid-PET, and tau-PET standardized uptake value ratio, automated WMH volume, and cognition using Pearson partial correlation after adjusting for age. We also evaluated vendor compatibility and reproducibility of the Fazekas scales using intraclass correlations (ICC). Periventricular and deep WMH measurements showed similar correlations with age, cardiometabolic conditions score (vascular risk), and cognition, (p < 0.001). Both periventricular WMH and deep WMH showed weak associations with amyloidosis (R = 0.07, p = < 0.001), and none with tau burden. We found substantial agreement between data from the two scanners for Fazekas measurements (ICC = 0.82 and 0.74). The automated WMH volume had high discriminating power for identifying participants with Fazekas ≥ 2 (area under curve = 0.97) and showed poor correlation with amyloid and tau PET markers similar to the visual grading. Our study investigated risk factors underlying WMH spatial patterns and their impact on global cognition, with no discernible differences between periventricular and deep WMH. We observed minimal impact of amyloidosis on WMH severity. These findings, coupled with enhanced inter-scanner reproducibility of WMH data, suggest the combinability of inter-scanner data assessed by harmonized protocols in the context of vascular contributions to cognitive impairment and dementia biomarker research.","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"20 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141572977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Polygenic effects on the risk of Alzheimer’s disease in the Japanese population","authors":"Masataka Kikuchi, Akinori Miyashita, Norikazu Hara, Kensaku Kasuga, Yuko Saito, Shigeo Murayama, Akiyoshi Kakita, Hiroyasu Akatsu, Kouichi Ozaki, Shumpei Niida, Ryozo Kuwano, Takeshi Iwatsubo, Akihiro Nakaya, Takeshi Ikeuchi","doi":"10.1186/s13195-024-01514-8","DOIUrl":"https://doi.org/10.1186/s13195-024-01514-8","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Correction: Alz Res Therapy 16, 45 (2024)&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;https://doi.org/10.1186/s13195-024-01414-x&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p&gt;Following publication of the original article [1], the authors corrected an error in Fig. 2.&lt;/p&gt;&lt;figure&gt;&lt;figcaption&gt;&lt;b data-test=\"figure-caption-text\"&gt;Fig. 2&lt;/b&gt;&lt;/figcaption&gt;&lt;picture&gt;&lt;source srcset=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13195-024-01514-8/MediaObjects/13195_2024_1514_Fig1_HTML.png?as=webp\" type=\"image/webp\"/&gt;&lt;img alt=\"figure 1\" aria-describedby=\"Fig1\" height=\"730\" loading=\"lazy\" src=\"//media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13195-024-01514-8/MediaObjects/13195_2024_1514_Fig1_HTML.png\" width=\"685\"/&gt;&lt;/picture&gt;&lt;p&gt;The PRS.noAPOE and PRS.adjLD correlated with CSF Tau/Aβ42 ratios in the MCI. CSF tTau/Aβ42 (&lt;b&gt;A&lt;/b&gt;, &lt;b&gt;C&lt;/b&gt;) and pTau/Aβ42 (&lt;b&gt;B&lt;/b&gt;, &lt;b&gt;D&lt;/b&gt;) ratios by decile of PRS are shown in each diagnostic group. The participants were divided into ten groups based on the PRS.noAPOE, ranging from the lowest group (1st decile) to the highest group (10th decile). CN = cognitively normal; MCI = mild cognitive impairment; ADD = Alzheimer’s disease dementia&lt;/p&gt;&lt;span&gt;Full size image&lt;/span&gt;&lt;svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"&gt;&lt;use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/figure&gt;&lt;p&gt;&lt;b&gt;Error:&lt;/b&gt; Figs. 2C and D are the same figures as Figs. 2A and B in the published article.&lt;/p&gt;&lt;p&gt;The corrected figure is given below:&lt;/p&gt;&lt;p&gt;The original article [1] has been updated.&lt;/p&gt;&lt;ol data-track-component=\"outbound reference\" data-track-context=\"references section\"&gt;&lt;li data-counter=\"1.\"&gt;&lt;p&gt;Kikuchi M, Miyashita A, Hara N, et al. Polygenic effects on the risk of Alzheimer’s disease in the Japanese population. Alz Res Therapy. 2024;16:45. https://doi.org/10.1186/s13195-024-01414-x.&lt;/p&gt;&lt;p&gt;Article CAS Google Scholar &lt;/p&gt;&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;Download references&lt;svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"&gt;&lt;use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/p&gt;&lt;h3&gt;Authors and Affiliations&lt;/h3&gt;&lt;ol&gt;&lt;li&gt;&lt;p&gt;Department of Computational Biology and Medical Sciences, Graduate School of Frontier Science, The University of Tokyo, 6‑2‑3 Kashiwanoha, Kashiwa, Chiba, 277‑0882, Japan&lt;/p&gt;&lt;p&gt;Masataka Kikuchi &amp; Akihiro Nakaya&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Department of Medical Informatics, Graduate School of Medicine, Osaka University, Osaka, Japan&lt;/p&gt;&lt;p&gt;Masataka Kikuchi&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Department of Molecular Genetics, Brain Research Institute, Niigata University, 1‑757 Asahimachi, Niigata, 951‑8585, Japan&lt;/p&gt;&lt;p&gt;Akinori Miyashita, Norikazu Hara, Kensaku Kasuga &amp; Takeshi Ikeuchi&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Brain Bank for Aging Research (Department of Neuropathology), Tokyo Metropolitan Institute of Geriatrics and Gerontology, Tokyo, Japan&lt;/p&gt;&lt;p&gt;Yuko Saito &amp; Shigeo Murayama&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Brain Bank for Neurodevelopmental, Neurological and Psyc","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"3 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141573204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease","authors":"Lawrence S. Honig, Marwan N. Sabbagh, Christopher H. van Dyck, Reisa A. Sperling, Steven Hersch, Andre Matta, Luigi Giorgi, Michelle Gee, Michio Kanekiyo, David Li, Derk Purcell, Shobha Dhadda, Michael Irizarry, Lynn Kramer","doi":"10.1186/s13195-024-01507-7","DOIUrl":"https://doi.org/10.1186/s13195-024-01507-7","url":null,"abstract":"&lt;p&gt;&lt;b&gt;Correction: &lt;/b&gt;&lt;b&gt;&lt;i&gt;Alz Res Therapy &lt;/i&gt;&lt;/b&gt;&lt;b&gt;16, 105 (2024)&lt;/b&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;https://doi.org/10.1186/s13195-024-01441-8&lt;/b&gt;&lt;/p&gt;&lt;p&gt;Following publication of the original article [1], several typographical errors were observed:&lt;/p&gt;&lt;ul&gt;\u0000&lt;li&gt;\u0000&lt;p&gt;In Table 2, recurrent ARIA-E for ApoE carriers should be 3.8% (not 11.7%).&lt;/p&gt;\u0000&lt;/li&gt;\u0000&lt;li&gt;\u0000&lt;p&gt;In Table 2, there were several incorrect indentations for several rows (old and updated versions of Table 2 are presented below).&lt;/p&gt;\u0000&lt;/li&gt;\u0000&lt;li&gt;\u0000&lt;p&gt;There are two places on page 6 where ‘ARIA-E’ should be ‘ARIA’.&lt;/p&gt;\u0000&lt;/li&gt;\u0000&lt;li&gt;\u0000&lt;p&gt;In Table 5, the asterisk in right column should be a superscript ‘1’. The footnote should have an end parenthesis at end of the footnote sentence below the table.&lt;/p&gt;\u0000&lt;/li&gt;\u0000&lt;/ul&gt;&lt;p&gt;Moreover, Supplementary material 1 (.docx) has been replaced with its pdf version with modification in Table S4 - ID21 (the participant should be “male” instead of “female”).&lt;/p&gt;&lt;p&gt;The old version of Table 2:&lt;/p&gt;&lt;figure&gt;&lt;figcaption&gt;&lt;b data-test=\"table-caption\"&gt;Table 2 Adverse events and ARIA in Clarity Core and Core + OLE&lt;/b&gt;&lt;/figcaption&gt;&lt;span&gt;Full size table&lt;/span&gt;&lt;svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"&gt;&lt;use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/figure&gt;&lt;p&gt;The updated version of Table 2:&lt;/p&gt;&lt;figure&gt;&lt;figcaption&gt;&lt;b data-test=\"table-caption\"&gt;Table 2 Adverse events and ARIA in Clarity Core and Core + OLE&lt;/b&gt;&lt;/figcaption&gt;&lt;span&gt;Full size table&lt;/span&gt;&lt;svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"&gt;&lt;use xlink:href=\"#icon-eds-i-chevron-right-small\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/figure&gt;&lt;p&gt;The original article [1] has been updated.&lt;/p&gt;&lt;ol data-track-component=\"outbound reference\" data-track-context=\"references section\"&gt;&lt;li data-counter=\"1.\"&gt;&lt;p&gt;Honig LS, Sabbagh MN, van Dyck CH, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease. Alz Res Therapy. 2024;16:105. https://doi.org/10.1186/s13195-024-01441-8&lt;/p&gt;&lt;p&gt;Article CAS Google Scholar &lt;/p&gt;&lt;/li&gt;&lt;/ol&gt;&lt;p&gt;Download references&lt;svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"&gt;&lt;use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"&gt;&lt;/use&gt;&lt;/svg&gt;&lt;/p&gt;&lt;h3&gt;Authors and Affiliations&lt;/h3&gt;&lt;ol&gt;&lt;li&gt;&lt;p&gt;Columbia University Irving Medical Center, NYS Center of Excellence for Alzheimer’s Disease, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Gertrude H. Sergievsky Center (PH19), &amp; Department of Neurology, Columbia University Vagelos College of Physicians &amp; Surgeons, 630 West 168th Street (P&amp;S UNIT 16), New York, NY, 10032-3795, USA&lt;/p&gt;&lt;p&gt;Lawrence S. Honig&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Barrow Neurological Institute, Phoenix, AZ, 85013, USA&lt;/p&gt;&lt;p&gt;Marwan N. Sabbagh&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Yale School of Medicine, New Haven, CT, USA&lt;/p&gt;&lt;p&gt;Christopher H. van Dyck&lt;/p&gt;&lt;/li&gt;&lt;li&gt;&lt;p&gt;Brigham and Women’s Hospital, Massachusetts General Hospital, H","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"4 1","pages":""},"PeriodicalIF":9.0,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141572978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative transport mapping of multi-delay arterial spin labeling MRI detects early blood perfusion alterations in Alzheimer's disease.","authors":"Yihao Guo, Liangdong Zhou, Yi Li, Gloria C Chiang, Tao Liu, Huijuan Chen, Weiyuan Huang, Mony J de Leon, Yi Wang, Feng Chen","doi":"10.1186/s13195-024-01524-6","DOIUrl":"10.1186/s13195-024-01524-6","url":null,"abstract":"<p><strong>Background: </strong>Quantitative transport mapping (QTM) of blood velocity, based on the transport equation has been demonstrated higher accuracy and sensitivity of perfusion quantification than the traditional Kety's method-based cerebral blood flow (CBF). This study aimed to investigate the associations between QTM velocity and cognitive function in Alzheimer's disease (AD) using multiple post-labeling delay arterial spin labeling (ASL) MRI.</p><p><strong>Methods: </strong>A total of 128 subjects (21 normal controls (NC), 80 patients with mild cognitive impairment (MCI), and 27 AD) were recruited prospectively. All participants underwent MRI examination and neuropsychological evaluation. QTM velocity and traditional CBF maps were computed from multiple delay ASL. Regional quantitative perfusion measurements were performed and compared to study group differences. We tested the hypothesis that cognition declines with reduced cerebral blood perfusion with consideration of age and gender effects.</p><p><strong>Results: </strong>In cortical gray matter (GM) and the hippocampus, QTM velocity and CBF showed decreased values in the AD group compared to NC and MCI groups; QTM velocity, but not CBF, showed a significant difference between MCI and NC groups. QTM velocity and CBF showed values decreasing with age; QTM velocity, but not CBF, showed a significant gender difference between male and female. QTM velocity and CBF in the hippocampus were positively correlated with cognition, including global cognition, memory, executive function, and language function.</p><p><strong>Conclusion: </strong>This study demonstrated an increased sensitivity of QTM velocity as compared with the traditional Kety's method-based CBF. Specifically, we observed only in QTM velocity, reduced perfusion velocity in GM and the hippocampus in MCI compared with NC. Both QTM velocity and CBF demonstrated a reduction in AD vs. controls. Decreased QTM velocity and CBF in the hippocampus were correlated with poor cognitive measures. These findings suggest QTM velocity as potential biomarker for early AD blood perfusion alterations and it could provide an avenue for early intervention of AD.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"156"},"PeriodicalIF":7.9,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11229285/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141557777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer's disease.","authors":"Matthew D Howe, Karysa J Britton, Hannah E Joyce, William Menard, Sheina Emrani, Zachary J Kunicki, Melanie A Faust, Brittany C Dawson, Meghan C Riddle, Edward D Huey, Shorena Janelidze, Oskar Hansson, Stephen P Salloway","doi":"10.1186/s13195-024-01521-9","DOIUrl":"10.1186/s13195-024-01521-9","url":null,"abstract":"<p><strong>Background: </strong>With the approval of disease-modifying treatments (DMTs) for early Alzheimer's disease (AD), there is an increased need for efficient and non-invasive detection methods for cerebral amyloid-β (Aβ) pathology. Current methods, including positron emission tomography (PET) and cerebrospinal fluid (CSF) analysis, are costly and invasive methods that may limit access to new treatments. Plasma tau phosphorylated at threonine-217 (P-tau217) presents a promising alternative, yet optimal cutoffs for treatment eligibility with DMTs like aducanumab require further investigation. This study evaluates the efficacy of one- and two-cutoff strategies for determining DMT eligibility at the Butler Hospital Memory & Aging Program (MAP).</p><p><strong>Methods: </strong>In this retrospective, cross-sectional diagnostic cohort study, we first developed P-tau217 cutoffs using site-specific and BioFINDER-2 training data, which were then tested in potential DMT candidates from Butler MAP (total n = 150). ROC analysis was used to calculate the area under the curve (AUC) and accuracy of P-tau217 interpretation strategies, using Aβ-PET/CSF testing as the standard of truth.</p><p><strong>Results: </strong>Potential DMT candidates at Butler MAP (n = 50), primarily diagnosed with mild cognitive impairment (n = 29 [58%]) or mild dementia (21 [42%]), were predominantly Aβ-positive (38 [76%]), and half (25 [50%]) were subsequently treated with aducanumab. Elevated P-tau217 predicted cerebral Aβ positivity in potential DMT candidates (AUC = 0.97 [0.92-1]), with diagnostic accuracy ranging from 0.88 (0.76-0.95, p = 0.028) to 0.96 (0.86-1, p < .001). When using site-specific cutoffs, a subset of DMT candidates (10%) exhibited borderline P-tau217 (between 0.273 and 0.399 pg/mL) that would have potentially required confirmatory testing.</p><p><strong>Conclusions: </strong>This study, which included participants treated with aducanumab, confirms the utility of one- and two-cutoff strategies for interpreting plasma P-tau217 in assessing DMT eligibility. Using P-tau217 could potentially replace more invasive diagnostic methods, and all aducanumab-treated participants would have been deemed eligible based on P-tau217. However, false positives remain a concern, particularly when applying externally derived cutoffs that exhibited lower specificity which could have led to inappropriate treatment of Aβ-negative participants. Future research should focus on prospective validation of P-tau217 cutoffs to enhance their generalizability and inform standardized treatment decision-making across diverse populations.</p>","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"154"},"PeriodicalIF":7.9,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid angiopathy.","authors":"Ingeborg Rasing, Sabine Voigt, Emma A Koemans, Anna M de Kort, Thijs W van Harten, Ellis S van Etten, Erik W van Zwet, Erik Stoops, Cindy Francois, H Bea Kuiperij, Catharina J M Klijn, Floris H B M Schreuder, Louise van der Weerd, Matthias J P van Osch, Marianne A A van Walderveen, Marcel M Verbeek, Gisela M Terwindt, Marieke J H Wermer","doi":"10.1186/s13195-024-01518-4","DOIUrl":"10.1186/s13195-024-01518-4","url":null,"abstract":"","PeriodicalId":7516,"journal":{"name":"Alzheimer's Research & Therapy","volume":"16 1","pages":"155"},"PeriodicalIF":7.9,"publicationDate":"2024-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11227145/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}